Intravenöse Immunglobuline sind die Therapie der ersten Wahl bei der CIDP

Pro

Entscheidende Grundlage einer erfolgreichen Therapie der chronisch inflammatorischen demyelinisierenden Polyradikuloneuropathie (CIDP) ist die korrekte Diagnose. Zur medikamentösen Behandlung der CIDP werden effektiv, d. h. symptomverbessernd, seit den 1950er-Jahren Glukokortikoide (Evidenzklasse Ib) eingesetzt. Seit den 1980er-Jahren stehen zudem i. v. Immunglobuline (IVIg) zur Verfügung.

• Literatur

• 1 van Doorn PA, Merkies IS. How to assess new drugs for neuropathies: advances in trial design and methodology. Curr Opin Neurol 2008; 21: 519-526
• 2 Hughes RA, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332
• 3 Cocito D, Paolasso I, Antonini G et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294
• 4 Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144
• 5 Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201
• 6 Ropper AH. Current treatments for CIDP. Neurology 2003; 60: 16-22
• 7 Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11: 493-502
• 8 Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci 2013; 34: 445-457
• 9 Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. Journal of neuroimmunology 2011; 231: 61-69
• 10 Rosen FS. Putative mechanisms of the effect of intravenous gamma-globulin. Clin Immunol Immunopathol 1993; 67: 41-43
• 11 Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. The Journal of clinical investigation 1994; 94: 1729-1735
• 12 Hartung HP. Advances in the understanding of the mechanism of action of IVIg. Journal of neurology 2008; 255 (Suppl. 03) 3-6
• 13 Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003; 135: 91-95
• 14 Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792
• 15 Bick S, Tschernatsch M, Karg A et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy – a new mechanism of action?. J Neuroimmunol 2013; 256: 84-90
• 16 Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-545
• 17 Lin CS, Krishnan AV, Park SB et al. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68: 862-869
• 18 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412
• 19 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord 2012; 5: 359-373
• 20 Latov N, Deng C, Dalakas MC et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurology 2010; 67: 802-807
• 21 Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2009; CD001797
• 22 Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2012; (08) CD002062
• 23 Merkies IS, van Nes SI, Hanna K et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 2010; 81: 1194-1199
• 24 Donofrio PD, Bril V, Dalakas MC et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082-1088
• 25 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic advances in neurological disorders 2012; 5: 359-373
• 26 Hughes R. The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol 2008; 255 (Suppl. 03) 7-11
• 27 Blackhouse G, Gaebel K, Xie F et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8: 14
• 28 Bae SC, Corzillius M, Kuntz KM et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 46-53